WallStSmart

International Flavors & Fragrances Inc (IFF)vsVersamet Royalties Corporation Common Stock (VMET)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

International Flavors & Fragrances Inc generates 14433% more annual revenue ($10.78B vs $74.18M). VMET leads profitability with a 49.9% profit margin vs 2.6%. VMET earns a higher WallStSmart Score of 60/100 (C+).

IFF

Hold

46

out of 100

Grade: D+

Growth: 2.7Profit: 4.5Value: 6.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.04

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.0Value: 5.3Quality: 4.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IFFUndervalued (+63.6%)

Margin of Safety

+63.6%

Fair Value

$211.67

Current Price

$85.85

$125.82 discount

UndervaluedFair: $211.67Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IFF1 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

VMET5 strengths · Avg: 9.6/10
Profit MarginProfitability
49.9%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
58.0%10/10

Strong operational efficiency at 58.0%

Revenue GrowthGrowth
391.9%10/10

Revenue surging 391.9% year-over-year

EPS GrowthGrowth
2123.0%10/10

Earnings expanding 2123.0% YoY

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

IFF4 concerns · Avg: 3.5/10
PEG RatioValuation
1.714/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.8%4/10

1.8% revenue growth

Return on EquityProfitability
2.1%3/10

ROE of 2.1% — below average capital efficiency

Profit MarginProfitability
2.6%3/10

2.6% margin — thin

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

Market CapQuality
$1.03B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : IFF

The strongest argument for IFF centers on Price/Book.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.

Bear Case : IFF

The primary concerns for IFF are PEG Ratio, Revenue Growth, Return on Equity. Thin 2.6% margins leave little buffer for downturns.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

IFF profiles as a value stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 391.9% — sustainability is the question.

IFF generates stronger free cash flow (284M), providing more financial flexibility.

Monitor SPECIALTY CHEMICALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VMET scores higher overall (60/100 vs 46/100), backed by strong 49.9% margins and 391.9% revenue growth. IFF offers better value entry with a 63.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

International Flavors & Fragrances Inc

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

International Flavors & Fragrances is an American corporation that produces flavors, fragrances, and cosmetic actives, which it markets globally. It is headquartered in New York City.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?